Matas A J, Smith J M, Skeans M A, Thompson B, Gustafson S K, Schnitzler M A, Stewart D E, Cherikh W S, Wainright J L, Snyder J J, Israni A K, Kasiske B L
Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN; Department of Surgery, University of Minnesota, Minneapolis, MN.
Am J Transplant. 2014 Jan;14 Suppl 1:11-44. doi: 10.1111/ajt.12579.
For most end-stage renal disease patients, successful kidney transplant provides substantially longer survival and better quality of life than dialysis, and preemptive transplant is associated with better outcomes than transplants occurring after dialysis initiation. However, kidney transplant numbers in the us have not changed for a decade. Since 2004, the total number of candidates on the waiting list has increased annually. Median time to transplant for wait-listed adult patients increased from 2.7 years in 1998 to 4.2 years in 2008. The discard rate of deceased donor kidneys has also increased, and the annual number of living donor transplants has decreased. The number of pediatric transplants peaked at 899 in 2005, and has remained steady at approximately 750 over the past 3 years; 40.9% of pediatric candidates undergo transplant within 1 year of wait-listing. Graft survival continues to improve for both adult and pediatric recipients. Kidney transplant is one of the most cost-effective surgical interventions; however, average reimbursement for recipients with primary Medicare coverage from transplant through 1 year posttransplant was comparable to the 1-year cost of care for a dialysis patient. Rates of rehospitalization are high in the first year posttransplant; annual costs after the first year are lower.
对于大多数终末期肾病患者而言,成功的肾移植比透析能显著延长生存期并提高生活质量,而且预先移植比透析开始后进行的移植预后更好。然而,美国的肾移植数量十年来一直没有变化。自2004年以来,等待名单上的候选者总数每年都在增加。等待移植的成年患者的中位移植时间从1998年的2.7年增加到了2008年的4.2年。已故捐赠者肾脏的丢弃率也有所上升,活体捐赠者移植的年度数量则有所下降。儿科移植数量在2005年达到899例的峰值,在过去3年中一直稳定在约750例;40.9%的儿科候选者在列入等待名单的1年内接受了移植。成年和儿科受者的移植物存活率都在持续提高。肾移植是最具成本效益的外科手术干预措施之一;然而,主要医疗保险覆盖的受者从移植到移植后1年的平均报销费用与透析患者1年的护理费用相当。移植后第一年的再住院率很高;第一年之后的年度费用较低。